Skip to content

Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05848986
Acronym
FERIplaq
Enrollment
20
Registered
2023-05-08
Start date
2023-06-01
Completion date
2025-04-01
Last updated
2023-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms. The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases. The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

Interventions

OTHERFlow cytometry

Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years-old * With a protein/drug allergy (hymenoptera, arachide, amoxicillin) * Confirmed by skin tests and/or challenge test * With specific IgEs

Exclusion criteria

* Patients who refuse to participate to this study * Patients unable to consent

Design outcomes

Primary

MeasureTime frameDescription
Presence of functionnal FcERI/RII receptors on the surface of blood platelets from allergic patients1 dayAfter confirmation of the allergy by a well conducted allergy workup

Countries

France

Contacts

Primary ContactCHARLES AMBROISE TACQUARD, MD
charlesambroise.tacquard@chru-strasbourg.fr03 69 55 16 08

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026